Liquidia Corporation to Showcase Innovations at Investor Conferences
![Liquidia Corporation to Showcase Innovations at Investor Conferences](https://investorshangout.com/images/blog/ihnews-Liquidia%20Corporation%20to%20Showcase%20Innovations%20at%20Investor%20Conferences.jpg)
Liquidia Corporation to Present at Upcoming Investor Conferences
Liquidia Corporation (NASDAQ: LQDA), a pioneering biopharmaceutical company dedicated to developing groundbreaking therapies for patients with rare cardiopulmonary diseases, has announced its participation in several significant investor conferences this September. These events present an excellent opportunity for Liquidia to showcase its innovative products and convey its future strategies to investors and industry stakeholders.
Upcoming Investor Conference Schedule
Liquidia Corporation will be featured at two notable investor conferences:
Wells Fargo Healthcare Conference
The first event is the 2024 Wells Fargo Healthcare Conference, which will be held in Boston. Liquidia is scheduled to present on Thursday, September 5, 2024, from 11:00 to 11:35 a.m. ET. This conference is known for bringing together leading healthcare companies and investors, providing a platform for networking and strategic discussions.
Cantor Global Healthcare Conference
The next stop for Liquidia Corporation will be the 2024 Cantor Global Healthcare Conference in New York, where the company will present on Thursday, September 19, 2024, from 1:30 to 1:50 p.m. ET. This conference is an important venue for biopharmaceutical companies to discuss their latest advancements and operational goals with potential and current investors.
Accessing the Presentations
Investors and interested parties will have the opportunity to access the webcasts of these presentations by visiting the official Liquidia Corporation website. An archived recorded version of each presentation will also be available for at least 30 days following the event, ensuring that stakeholders can review the content at their convenience.
About Liquidia Corporation
Liquidia Corporation is committed to advancing therapeutics for patients suffering from rare cardiopulmonary diseases. The company is engaged in the development and commercialization of innovative products in areas such as pulmonary hypertension. Their proprietary PRINT Technology has been instrumental in creating their lead product candidate, YUTREPIA™ (treprostinil) inhalation powder. This investigational drug targets pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Furthermore, Liquidia is progressing on L606, a sustained-release formulation of treprostinil that is administered twice-daily via a next-generation nebulizer. The company also markets a generic form of Treprostinil Injection specifically for the treatment of PAH. Liquidia's ongoing development projects and innovative technology solidify its role as a leader in the biopharmaceutical sector focused on pulmonary health.
Contact Information
Investors:
Jason Adair
919.328.4350
jason.adair@liquidia.com
Media:
Patrick Wallace
919.328.4383
patrick.wallace@liquidia.com
Frequently Asked Questions
What is Liquidia Corporation known for?
Liquidia Corporation is known for developing innovative therapies aimed at treating rare cardiopulmonary diseases.
When will Liquidia present at investor conferences?
Liquidia will present at the Wells Fargo Healthcare Conference on September 5, 2024, and at the Cantor Global Healthcare Conference on September 19, 2024.
How can investors access the presentations?
Investors can access the webcasts of the presentations on Liquidia's official website, where archived versions will also be available for at least 30 days following each event.
What products are Liquidia developing?
Liquidia is developing YUTREPIA™ for PAH and L606, a sustained-release formulation of treprostinil, along with marketing a generic version of Treprostinil Injection.
Who should be contacted for investor inquiries?
For investor inquiries, Jason Adair is the primary contact at 919.328.4350 or via email at jason.adair@liquidia.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- FFW Corporation Declares $0.30 Quarterly Dividend
- NewtekOne, Inc. CEO Barry Sloane to Attend Key Conference
- AUGA group, AB Investor Conference Webinar Details
- Public Opening Position Disclosure by Rathbones Group Plc
- Loupe Offers Exciting Rewards for Topps Chrome Basketball
- DCHFA Relaunches ReMIT Program to Assist Seniors
- RealManage Achieves 2024 Great Place to Work Certification
- Maternal Nutrition Products Market Set to Reach $38.66 Billion
- Security Robots Market Set for Growth to USD 29.65 Billion
- Banle Group Boosts Global Port Network to 60+ Ports